Vitiligo Pipeline Review, H2 2020: Overview of the Vitiligo (Dermatology) Pipeline Landscape Featuring 21 Key Players - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 25, 2021--
The “Vitiligo - Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Vitiligo - Pipeline Review, H2 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape.
Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.
The Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 3, 1, 11 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.
Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
Key Topics Covered:
- Vitiligo - Overview
- Vitiligo - Therapeutics Development
- Vitiligo - Therapeutics Assessment
- Vitiligo - Companies Involved in Therapeutics Development
- Vitiligo - Drug Profiles
- Vitiligo - Dormant Projects
- Vitiligo - Discontinued Products
- Vitiligo - Product Development Milestones
- 2A Pharma AB
- Aclaris Therapeutics Inc
- Alexion Pharmaceuticals Inc
- Amgen Inc
- AnTolRx Inc
- Arrien Pharmaceuticals LLC
- Avotres Inc
- Boston Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Clinuvel Pharmaceuticals Ltd
- Incyte Corp
- Innovision Therapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- JN Biosciences LLC
- Pfizer Inc
- Radikal Therapeutics Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- TagCyx Biotechnologies
- Temprian Therapeutics Inc
- TWi Biotechnology Inc
- Villaris Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ufrp71
View source version on businesswire.com:https://www.businesswire.com/news/home/20210325005720/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 03/25/2021 11:59 AM/DISC: 03/25/2021 11:59 AM